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INTRODUCTION
Non-small cell lung cancer accounts for 87% of all lung cancers diagnosed in the UK (1).
Lung adenocarcinomas can be further stratified according to the mutation status (2) .
Epidermal growth factor receptor (EGFR), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) and anaplastic lymphoma kinase (ALK) are currently the mutations most commonly tested for in lung adenocarcinomas. The stratification of lung adenocarcinomas according to these molecular subtypes has important clinical implications, informing the first-line treatment offered to each individual patient (2) .
Activating EGFR mutations were first described in 2004 as patients with mutations in EGFR gene were found to show clinical response to EGFR tyrosine kinase inhibitors (TKIs) (3) . This discovery revolutionized the molecular diagnostic for lung cancer patients. Two of the most commonly occurring mutations, exon 19 deletions and exon 21 L858R missense mutations confer sensitivity to EGFR TKIs (3) . In contrast, exon 20 T790M mutations are associated with resistance to EGFR TKIs (4).
The identification of echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) fusion gene in a subgroup of NSCLC (5) as an oncogenic driver has led to the development of ALK inhibitors that show a dramatic and long-lived response in ALK-translocated tumours (6) . ALK abnormalities are typically associated with younger age and never smokers (7) . KRAS mutations in NSCLC occur more frequently in Caucasian populations and are associated with smoking (8) . G12C and G12V subtypes are commonly found in patients with a smoking history whereas G12D is more likely to be found in non-smokers (9) .
The aim of this study was to evaluate the utility of ALK immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) and to determine the prevalence of EGFR, KRAS and ALK mutations.
METHODS

Specimens, demographics and clinical information
From January 2011 to May 2014, a total of 682 cases in SE Scotland were tested for the presence of EGFR, KRAS mutations and/or ALK rearrangements. This comprised 586 adenocarcinomas, 75 non-small cell lung carcinomas and 21 other tumours (including 6 cases of large cell neuroendocrine carcinoma, 4 cases of squamous cell carcinoma, 3
cases of large cell undifferentiated carcinoma, 2 mixed adenosquamous carcinoma, 1 case each of mixed squamous and large cell neuroendocrine carcinoma, carcinoid tumour, pleomorphic carcinoma, sarcoma, sarcomatoid carcinoma and mixed malignant peripheral nerve sheath tumour and large cell neuroendocrine carcinoma). Common to these 21 other tumours was young age and/or a history of non-smoking which was deemed by the oncologist as a reason for molecular testing. Of these 37 samples were insufficient due to low volume of tumour or tissue. In January 2013, KRAS mutation testing was introduced and was carried out on 242 cases. ALK rearrangement testing was introduced in 2012 and carried out on 304 cases. Most of these samples were biopsy specimens, 428 followed by 160 cell blocks (prepared from cytological specimens such as EBUS aspirates or pleural fluids), and 94 surgically resected samples either from the primary tumour or site of metastasis. Clinical data and demographics of all patients were collected retrospectively from electronic clinical records. This study was conducted as part of an audit on the clinical testing services for lung adenocarcinomas in molecular pathology. Lung cancer staging was done in accordance with the 7 th Edition "TNM classification of malignant tumours" (10) . Smoking status was classified as never smokers (<100 cigarettes in lifetime), former smokers (stopped smoking for at least one year before diagnosis) and current smokers (including those who stopped smoking less than one year prior to diagnosis) (9) . Smoking exposure was measured in pack years whereby one pack year was defined as smoking 20 cigarettes per day in one year.
ALK, EGFR and KRAS mutation testing
ALK IHC was carried out using the D5F3 clone The EGFR and KRAS mutation status was determined using DNA extracted from formalin-fixed, paraffin embedded sections. Macrodissection was carried out on a large number of cases to enrich the tumour DNA. The amount of tissue used varied from 3 to 6 10µm thick sections depending on the amount of tumour tissue present in each case.
DNA was analysed for 29 EGFR mutations using the Qiagen's therascreen® EGFR RGQ PCR method. KRAS testing was carried out using an in-house pyrosequencing method to detect mutations in codons 12, 13 and 61 of the KRAS oncogene using the primer sequences described (please see Supporting Information).
Statistical Analysis
Data were analysed using χ 2 test for association and trend (where categories were ordered, eg smoking). Where expected observations were less than 5, Fisher's Exact test was employed. Multivariable explanatory models were analysed using logistic regression.
RESULTS
Of 682 patients with lung cancer included 680 were tested for EGFR mutations, 304 for ALK and 242 for KRAS mutations concomitantly. Figure 2 .
DISCUSSION
The approval of EGFR and ALK TKIs for use in subsets of patients with activating mutations means there is a requirement to provide a molecular pathology service capable of multiplex testing in a cost-effective manner. As these mutations tend to be mutually exclusive (12), we have introduced KRAS testing as a tool to help select patients for ALK testing and at the same time enable a wise use of the budget. KRAS testing offers a more cost-effective and clinically useful alternative compared to ALK FISH testing (13) .
Moreover, despite not being linked to predicting a direct response to therapy, there is strong evidence that KRAS mutations are involved in the mechanism of resistance to crizotinib (14) and in addition, KRAS mutations act as a stronger predictor of response to EGFR TKI therapy than the EGFR mutation status alone (15) . Therefore, based on the reasons above, our testing algorithm for NSCLC testing includes EGFR, ALK IHC and/or FISH and KRAS mutations testing (13).
Our study reports the prevalence of EGFR, ALK and KRAS mutations in South East of Scotland as 10.4%, 2.3% and 35.8% respectively.
There is large variation in the prevalence of ALK abnormalities as highlighted in a large systematic review (7). This variation in reporting is due to the selection criteria, with some studies including squamous cell carcinomas in their testing algorithms. There is not much data published from UK based population studies but data presented at local or national meetings describes the actual prevalence of ALK rearrangement in lung NSCLC in the UK to be lower than initially reported at approximately 1 to 2% (unpublished data).
Although ALK rearrangements are mutually exclusive with EGFR and KRAS mutations in our cohort, small numbers of tumours with concomitant ALK and EGFR or ALK and KRAS mutations have been reported in the literature (16) . In our cohort six out of the seven ALK rearranged tumours were non-smokers, only one patient was identified to be a smoker.
We have not identified any false negative IHC negative / FISH positive cases and this could be due to the relative small numbers in out cohort. Other studies report a discrepancy rate of up to 24% possibly due to hierarchical screening (17) . While the method commonly used to detect ALK abnormalities is FISH, most labs are now adopting immunohistochemistry as a screen test followed by confirmatory FISH (18) . This is cost-effective and offers a quicker turn-around time. More importantly, a recent study argues that the detection of the ALK fusion protein by immunohistochemistry is superior to an ALK FISH test in predicting tumour response and survival to crizotinib (19) . In view of this new data and our own experience, molecular testing of lung NSCLC should include ALK immunohistochemistry either as a screening tool or perhaps as a primary diagnostic test to detect ALK rearrangements.
Variable EGFR mutation rates have been reported across the world. One study in a single centre in the US reported an EGFR mutation rate of 20%, while a European study reported EGFR mutation rate of as low as 4.9% in an unselected cohort of patients whereby all newly diagnosed NSCLC cases were screened for EGFR mutations (20).
Data from Asian populations generally report higher mutation rates, in some studies as high as 66.3% (21). One likely explanation for the higher prevalence reported in most studies, including our study, was the possible selection bias when referring cases for mutation testing. At the early stages of EGFR mutation testing services, undoubtedly most of the cases referred seemed likely to be selected on the basis of never smoking status and younger age.
Our study highlights the association of female gender and never smoking status with the presence of EGFR mutations. Among the non-smokers tested, 74.6% were female.
Despite the association found between the non-smoking status and the presence of EGFR mutations, we do not recommend using smoking status as a selection criterion for excluding smokers from EGFR testing. As demonstrated, EGFR mutations are also present in smokers and former smokers, although to a much lesser degree.
We demonstrate that in smokers with any smoking history, there is a significant association with an increased likelihood of KRAS mutations regardless of smoking pack years.
In conclusion, ALK protein expression in tumour cells is 100% sensitive and 96.6% 
